12 Greenway Plaza
15 articles about Memgen
Memgen Announces New Clinical Data on MEM-288 in Advanced/Metastatic NSCLC at ASCO 2023 Annual Meeting
Memgen, Inc., a clinical-stage biotechnology company today announced updated clinical data from its first-in-human study of MEM-288, an oncolytic viral therapy, in patients with advanced/metastatic refractory non-small cell lung cancer.
Memgen Reports Results From Its First-In-Human Clinical Trial of MEM-288 in Solid Tumors Refractory to Checkpoint Inhibitors at SITC 2022
Memgen, Inc., a biopharmaceutical company developing potentially life-saving cancer immunotherapies, presented the first clinical data for MEM-288, its oncolytic viral therapy, at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting in Boston, MA.
BioSpace Movers & Shakers, Nov. 19
11/19/2021Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Memgen Appoints Kevin M. Coveney as Chief Financial Officer
Memgen, Inc., a clinical-stage biotechnology company developing potentially life-saving cancer immunotherapies, announced that Kevin M. Coveney, CPA, has been appointed Chief Financial Officer.
Memgen Announces FDA Clearance of IND Application for MEM-288
Memgen, Inc. announced that the U.S. Food and Drug Administration has accepted its investigational new drug application for MEM-288, the company’s wholly-owned cancer immunotherapy candidate for the treatment of multiple solid tumors.
This week, the U.S. Food and Drug Administration accepted Investigational New Drug Applications for multiple companies, clearing the way for clinical development.
ImmunoCellular Therapeutics And Memgen Announce Letter Of Intent For Potential Joint Immuno-Oncology Collaboration
Memgen Announces Preclinical Results For Its ISF35 Cancer Immunotherapy With Checkpoint Inhibitors In Metastatic Melanoma
Memgen Announces Upcoming Presentation for ISF35 in Chronic Lymphocytic Leukemia at 2011 Memgen Annual Meeting
Memgen Announces Clinical and Preclinical Results for ISF35 in Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma
Memgen's ISF35 Sensitizes Leukemia Cells to Chemotherapy
Memgen's Clinical Trial Results of ISF35 for Chronic Lymphocytic Leukemia Selected for Presentation at American Society of Hematology 2009 Annual Meeting
Memgen Reports Positive Results for ISF35 in High-Risk Chronic Lymphocytic Leukemia
Memgen's ISF35 Clinical Trial Featured at American Society of Clinical Oncology Annual 2009 Meeting
Memgen's Clinical Results on Leukemia Selected for Presentation at 2008 American Society of Hematology Annual Meeting